Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsHBMHF 73 Interest Coverage is 11.43 as of Dec. 2025, which is 51% below its 10-year median of 23.11. GuruFocus rates HBMHF with a GF Score™ of 73/100 and a GF Value™ of $0.87. The stock has 4 warning signs investors should review. Among 376 Biotechnology companies, HBM Holdings ranks worse than 60.11% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. HBM Holdings's
Operating Income
for the
six
months ended in Dec. 2025 was $14.1 Mil. HBM Holdings's Interest Expense for the
six
months ended in Dec. 2025 was $-1.2 Mil.
HBM Holdings's interest coverage for the quarter that ended in Dec. 2025 was 11.43.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for HBM Holdings's Interest Coverage or its related term are showing as below:
HBMHF'
s Interest Coverage Range Over the Past 10 Years
Min: 5.85 Med: 23.11 Max: 40.51
Current: 40.51
HBMHF's Interest Coverage is ranked worse than 60.11% of 376
companies
in the Biotechnology industry
Industry Median: 106.135
vs HBMHF: 40.51
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
HBM Holdings Interest Coverage Related Terms
HBM Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for HBM Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HBMHF vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, HBM Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (HBMHF) has a Interest Coverage of 11.43 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on HBM Holdings and its competitors. This is 51% below median its historical median of 23.11. Over the past decade, HBM Holdings' Interest Coverage has ranged from 5.85 to 40.51. According to the industry distribution chart, HBM Holdings ranks #226 out of 376 companies in the Biotechnology industry, placing it in the top 60.1%.
Is HBM Holdings' Interest Coverage too high?
HBM Holdings' current Interest Coverage of 11.43 is 51% below median its 10-year median of 23.11. Over the past 10 years, this metric has ranged from a low of 5.85 to a high of 40.51. The Biotechnology industry median Interest Coverage is 106.14. HBM Holdings' value of 11.43 is 89.2% below this industry median. Based on the distribution chart, HBM Holdings ranks #226 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HBM Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #226 out of 376 companies for Interest Coverage. This places HBM Holdings in the lower half of its industry. The industry median Interest Coverage is 106.14. HBM Holdings' value of 11.43 is 89.2% below this benchmark. Historically, HBM Holdings' own Interest Coverage has ranged from 5.85 to 40.51 over the past decade. While the company's 10-year median is 23.11 vs. the industry median of 106.14, HBM Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current Interest Coverage of 11.43 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current Interest Coverage is 11.43, which is 51% below median its own 10-year median of 23.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
HBM Holdings (HBMHF) has a current Interest Coverage of 11.43. The stock's GF Value™ is $0.87, compared to a current price of $1.56 — trading 79.3% above its estimated fair value. The current Interest Coverage is 11.43, which is 51% below median its 10-year median of 23.11 and 89.2% below the Biotechnology industry median of 106.14. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For HBM Holdings (HBMHF), the current Interest Coverage is 11.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (HBMHF) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of $1.56 is trading 79.3% above its estimated GF Value™ of $0.87.
Key valuation signals for HBMHF:
Interest Coverage: 11.43 (51% below median its 10-year median of 23.11)
GF Value™: $0.87 vs. price of $1.56 (79.3% above fair value)
Industry Position: 89.2% below the Biotechnology median (#226 of 376)
No single metric tells the full story. See the HBMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score
Get the complete analysis for HBMHF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBMHF has been successfully added to your 
